ClinicaSpace.com
Clinical Research
News & Careers
 
Search the Site
    
 
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   
 News | News By Subject | News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Bayer AG (BAY.F) Bets $4 Billion on R8D and Sales From 5 Blockbuster Drugs


11/14/2012 7:17:10 AM

German pharmaceutical and chemical company Bayer AG (BAYN.XE) said Wednesday it sees peak annual sales potential of 5.5 billion euros ($7 billion) for its five new drugs Xarelto, Stivarga, Alpharadin, Aflibercept and Riociguat. Bayer now includes the new drug Riociguat, which helps to treat pulmonary hypertension, in its sales forecast. The company said late last year that it sees peak sales potential of at least EUR1 billion for the cancer drugs Alpharadin and Regorafenib, also known as Stivarga, as well as the eye medicine Aflibercept, also known as Eylea and VEGF Trap-Eye.

Read at News Release
Read at Reuters
Read at News Release


 Read Article at  Related Companies  News Categories
Bayer AG
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES